"Only clinical stage RhoA inhibitor globally"
That's right Michael. That means no competition at all. No standard treatment to beat. Easy to get approvals and fast tracks.
Just a hint of efficacy and it should be worth hundreds of millions to the market cap, because that's what it'll be worth to big pharma.
Still some hurdles to go, but with ptx you have bets on lots of horses!
cheers
"Only clinical stage RhoA inhibitor globally" That's right...
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
-0.002(4.17%) |
Mkt cap ! $37.04M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.6¢ | $94.55K | 2.033M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7000 | 4.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 550000 | 2 |
View Market Depth
| Last trade - 15.36pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
4.8¢ |
Change
-0.002 ( 2.04 %) |
||||
| Open | High | Low | Volume | ||
| 4.7¢ | 4.8¢ | 4.5¢ | 409565 | ||
| Last updated 15.51pm 03/05/2024 ? | |||||
| PTX (ASX) Chart |